{
    "clinical_study": {
        "@rank": "161571", 
        "arm_group": [
            {
                "arm_group_label": "RM-493 Once Daily", 
                "arm_group_type": "Active Comparator", 
                "description": "Once daily in the morning, equivalent PBO in evening."
            }, 
            {
                "arm_group_label": "RM-493 Split Dose", 
                "arm_group_type": "Active Comparator", 
                "description": "Split dose, one half in the morning and one half in the evening."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo in the morning, placebo in the evening."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the effects of a new daily subcutaneous (SC)\n      injectable formulation of RM-493 in healthy obese subjects on mean percent body weight loss\n      and other weight loss parameters, as well as Pharmacokinetic (PK) profile. The study is\n      designed to evaluate the efficacy and tolerability of RM-493 administered once or twice\n      daily. The study drug (RM-493 and placebo) will be administered in a blinded fashion."
        }, 
        "brief_title": "Phase 1b/2a Study to Evaluate Safety and Efficacy of RM-493 in Obese Patients", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Overweight", 
        "condition_browse": {
            "mesh_term": "Overweight"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Be between the age of 18 and 65 inclusive.\n\n          -  Able to provide voluntary, written informed consent with comprehension of all aspects\n             of the protocol, prior to any study procedures.\n\n          -  In good general health, without significant medical history, physical examination\n             findings, or clinical laboratory abnormalities.\n\n          -  Body Mass Index:  30 to 40 Kg/m2.\n\n          -  Stable body weight by subject report (+/- 5 Kg) during previous 6 months.\n\n          -  Blood pressure (<140/90 mmHg); may include stable dose (\u2265 30 days of use) of up to\n             two anti-hypertensive medications to achieve control and that are intended to remain\n             on a stable dose during the protocol.  Patients slightly out of range can participate\n             at the discretion of the investigator.\n\n          -  Willingness (during screening) and demonstrated ability (as witnessed in the clinic\n             prior to randomization) to self-administer study medication subcutaneously via a once\n             or twice daily SC injection using a small insulin syringe.\n\n          -  Willing to maintain a healthy diet and exercise regime throughout study as\n             recommended by counseling at study start.\n\n          -  Female subjects must have negative serum pregnancy test and must not be lactating.\n             For females able to bear children, a hormonal (i.e., oral, implantable, or\n             injectable) and single-barrier method (i.e., sponge), or a double-barrier method of\n             birth control (i.e., condom with spermicide) or abstinence must be used/ practiced\n             throughout the study and for 90 days following the study.\n\n          -  Females of non-childbearing potential, defined as surgically sterile (status post\n             hysterectomy, bilateral oophorectomy, or bilateral tubal ligation) or post-menopausal\n             for at least 12 months (and confirmed with a screening FSH level in the\n             post-menopausal lab range), do not require contraception during the study.\n\n          -  Males with female partners of childbearing potential must agree to a double barrier\n             method if they become sexually active during the study and for 90 days following the\n             study. Male subjects must not donate sperm for 90 days following their participation\n             in the study.\n\n        Exclusion Criteria:\n\n          -  Fasting blood glucose > than 140 mg/dL.\n\n          -  TSH level outside the normal range.\n\n          -  Creatinine > 1.5 times the upper limit of normal.\n\n          -  Liver function tests > 2 times the upper limit of normal.\n\n          -  Active or history of any significant medical condition including renal, hepatic,\n             pulmonary, gastrointestinal, cardiovascular, genitourinary, endocrine, immunologic,\n             metabolic, neurologic or hematological disease.\n\n          -  Patients with a history of the following:\n\n               1. Uncontrolled hypertension;\n\n               2. Diabetes requiring medical treatment;\n\n               3. Major depressive disorder within the last 2 years;\n\n               4. Any lifetime history of a suicide attempt;\n\n               5. Any suicidal ideation/behavior in the last month;\n\n               6. Other severe psychiatric disorders (e.g. schizophrenia, bipolar disorder, severe\n                  eating disorders including bulimia).\n\n          -  A PHQ-9 score of \u226515.\n\n          -  Any suicidal ideation of type 4 or 5 on the C-SSRS.\n\n          -  Prior bariatric surgery.\n\n          -  History or close family history (parents or siblings) of melanoma.\n\n          -  Significant dermatologic findings as part of the Screening comprehensive skin\n             evaluation performed by the dermatologist.  Any concerning lesions identified during\n             the screening period will be biopsied and results known to be benign prior to\n             randomization.  If the pre-treatment biopsy results are of concern, the patient will\n             be excluded from the study.\n\n          -  Currently treated with anorectic agents or drugs in last 2 months from screening with\n             anorexia as a frequent side event.\n\n          -  Taking more than 2 anti-hypertensive medications.\n\n          -  Acute illness or history of illness, which in the opinion of the Investigator, could\n             pose a threat or harm to the patient or obscure interpretation of laboratory test\n             results or interpretation of study data.\n\n          -  History of any malignancy, past or present, including skin cancer, multiple severely\n             dysplastic nevi, or nevoid basal cell carcinoma.\n\n          -  History of HIV infection or Hepatitis B or C.\n\n          -  History of significant drug hypersensitivity or anaphylaxis.\n\n          -  History of hypersensitivity to proteins (e.g., allergy shots).\n\n          -  Any clinically significant abnormalities on screening laboratories as determined by\n             the Investigator.\n\n          -  Abnormal 12-lead electrocardiogram (ECG) at screening, except minor deviations deemed\n             to be of no clinical significance by the Investigator.  QTcF must be < 450 ms.\n\n          -  Received any experimental drugs or devices or have participated in a clinical study\n             within 30 days prior to dosing.\n\n          -  Blood donation greater than 500 mL within 60 days prior to screening or intent to\n             donate up to 30 days after Final Study Visit.\n\n          -  Hospitalization for surgery within the 3 months prior to screening except for minor\n             outpatient procedures, or any planned hospitalizations during the study period.\n\n          -  Poor venous access or inability to tolerate venipuncture.\n\n          -  Inability to attend all study visits or comply with protocol requirements including\n             fasting and restrictions on concomitant medication intake.\n\n          -  Participation in weight loss programs during the study period, including nutritional\n             supplements/ replacements other than as recommended by nutritional counseling\n             provided at study start.\n\n          -  Use of prescription medications on a regular basis with the following exceptions:\n\n               1. Contraceptives (must be on for \u22653 months);\n\n               2. Hormone replacement therapy (must be on stable dose for \u22653 months);\n\n               3. Antihypertensives (<2 medications on a stable dose for \u2265 30 days);\n\n               4. Statins (dose must be \u2264 half the maximum dose; must be on a stable dose \u22653\n                  months);\n\n               5. Thyroxin (stable dose for \u2265 30 days);\n\n               6. The last use of any other prescription medication must have been greater than 5\n                  half-lives for the specific medication or at least 14 days prior to\n                  randomization, whichever is longer.\n\n          -  Women who are pregnant or are breast feeding.\n\n          -  Previously randomized and dosed in this study or previously exposed to RM-493.\n\n          -  History of alcohol or drug abuse within 5 years of Screening Visit.\n\n          -  Any other reason, which in the opinion of the Investigator would confound proper\n             evaluation of the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 17, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02041195", 
            "org_study_id": "RM-493-009"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "RM-493 Once Daily", 
                    "RM-493 Split Dose"
                ], 
                "intervention_name": "RM-493", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "RM-493 Once Daily", 
                    "Placebo"
                ], 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Overweight", 
        "lastchanged_date": "April 29, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madison", 
                        "country": "United States", 
                        "state": "Wisconsin"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "Staged, Phase 1b/Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety and Efficacy of RM 493, a Melanocortin 4 Receptor (MC4R) Agonist in Obese Patients Using a Once or Twice Daily Sub-Cutaneous Injection Formulation", 
        "other_outcome": [
            {
                "description": "The proportion of patients who achieve a \u2265 5 and 10% decrease in body weight in the active treatment group compared to placebo.", 
                "measure": "The proportion of patients who achieve a \u2265 5 and 10% decrease in body weight.", 
                "safety_issue": "No", 
                "time_frame": "Baseline to end of treatment (12 weeks)"
            }, 
            {
                "description": "Measurement of the effect of RM-493 on fasting glucose.", 
                "measure": "Effect of RM-493 on fasting glucose.", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline to end of treatment (12 weeks)"
            }, 
            {
                "description": "Measurement of the effect of RM-493 on waist circumference.", 
                "measure": "Effect of RM-493 on waist circumference", 
                "safety_issue": "No", 
                "time_frame": "Baseline to end of treatment (12 weeks)"
            }, 
            {
                "description": "Measurement of the change in the depression/suicidality score as assessed by Patient Health Questionnaire 9 (PHQ-9) and the Columbia Suicidality Severity Rating Scale (C-SSRS).", 
                "measure": "Change in depression/suicidality.", 
                "safety_issue": "Yes", 
                "time_frame": "Screening to end of treatment (12 weeks)"
            }
        ], 
        "overall_official": {
            "affiliation": "Rhythm Metabolic, Inc.", 
            "last_name": "Elizabeth Stoner, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "The effect of RM-493 (once or twice daily) vs. placebo on mean percent body weight loss.", 
                "measure": "Effect on mean percent weight loss", 
                "safety_issue": "No", 
                "time_frame": "Baseline to end of treatment (12 weeks)"
            }, 
            {
                "description": "Assessment of adverse events and clinical laboratory evaluations.", 
                "measure": "Safety and Tolerability of RM-493", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline to end of treatment (12 weeks)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02041195"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Measurement of effect on mean body weight (BW) loss.", 
                "measure": "Effect on mean body weight loss", 
                "safety_issue": "No", 
                "time_frame": "Baseline to end of treatment (12 weeks)"
            }, 
            {
                "description": "Frequent PK (trough) sampling throughout each stage of the study, including a 24-hour inpatient PK profile.", 
                "measure": "Effect of RM-493 on Pharmacokinetics (PK)", 
                "safety_issue": "No", 
                "time_frame": "Baseline to end of treatment (12 weeks)"
            }, 
            {
                "description": "The effect of RM-493 on ambulatory blood pressure monitoring parameters (ABPM).", 
                "measure": "Effect of RM-493 on ambulatory blood pressure monitoring (ABPM) in a subset of patients", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline, and over one 24-hr period between Days 8 and 15"
            }
        ], 
        "source": "Rhythm Metabolic, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Rhythm Metabolic, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}